Search Results - "van der Schans, Simon"

Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands by Hagendijk, Marije E., van der Schans, Simon, Boersma, Cornelis, Postma, Maarten J., van der Pol, Simon

“…Objectives Multiple studies showed positive effects of Lutetium-Octreotate (LO) treatment in neuroendocrine tumours. LO has been used in the Netherlands since…”
Get full text

Monitoring physical impact and recovery of pancreatic cancer treatment using consumer wearable health data: A case report by van der Schans, Cees P, van der Schans, Simon, van der Schans, Jurjen, Mylius, Caspar, Klaase, Joost

“…Consumer wearables health data may reflect the impact of pancreatic cancer and its treatment on cardiorespiratory fitness and the subsequent recovery after…”
Get full text

Investing in the Prevention of Communicable Disease Outbreaks: Fiscal Health Modelling-The Tool of Choice for Assessing Public Finance Sustainability by van der Schans, Simon, Schöttler, Marcel H, van der Schans, Jurjen, Connolly, Mark P, Postma, Maarten J, Boersma, Cornelis

“…National strategies for preparedness for future outbreaks of COVID-19 often include timely preparedness with vaccines. Fiscal health modelling (FHM) has…”
Get full text

The impact of patent expiry on drug prices: insights from the Dutch market by van der Schans, Simon, Vondeling, Gert T., Cao, Qi, van der Pol, Simon, Visser, Sipke, Postma, Maarten J., Rozenbaum, Mark H.

“…Background: Currently literature on the impact of patent expiry on drug prices is lacking. Objective: To determine the impact of patent expiration and generic…”
Get full text

Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in The Netherlands by Velikanova, Rimma, van der Schans, Simon, Bischof, Matthias, van Olden, Rudolf Walther, Postma, Maarten, Boersma, Cornelis

“…OBJECTIVESSpinal muscular atrophy (SMA) is a rare genetic disorder that causes progressive muscle weakness and paralysis. In its most common and severe form,…”
Get full text

A novel perspective on pharmaceutical R&D costs: opportunities for reductions by van der Schans, Simon, De Loos, Frans, Boersma, Cornelis, Postma, Maarten J, Büller, Hans

“…R&D costs as an element of medicines' pricing play a prominent role in the discussions regarding the affordability of medicine. This paper investigates the…”
Get more information

Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations by van der Schans, Simon, Goossens, Lucas M. A., Boland, Melinde R. S., Kocks, Janwillem W. H., Postma, Maarten J., van Boven, Job F. M., Rutten-van Mölken, Maureen P. M. H.

“…Background Worldwide, chronic obstructive pulmonary disease (COPD) is a highly prevalent chronic lung disease with considerable clinical and socioeconomic…”
Get full text